PYRIDOSTIGMINE BROMIDE TABLETS

File: 070396_jun_decls30_0001.txt
Page: 0001
Total Pages: 1

Subject: PYRIDOSTIGMINE BROMIDE TABLETS                                  

Unit: 24TH ID     

Parent  Organization: XVIII CORPS 

Box ID: BX001427

Folder Seq #:        310

Document Number:         12








                                                             AFZP-MD
                                                             17 January  1991

                                  INFORMATION PAPER

        SUBJECT:  Pyridostigmine  Bromide Tablets
        1. Purpose:  To outline  purpose and function of pyridostigmine
        bromide (PB) tablets.

        2. Facts:

            a.  P@ridostigmine Bromide (PB) tablets, also referred to as
                Nerve Agent Pyridostigmine Pre-treatment (NAPP) are part of
                the medical defense against nerve agent exposure. The
                mechanism of action is to partially "protect" the target
                enzyme in the body from nerve agent. When used alone, it
                does not prevent nerve agent injury after exposure, but
                instead enhances the drug therapy provided by the
                .standard use of the MARK I kit. It is primarily effective
                against Soman (GD). Studies indicate that PB pretreatment
                with MARK I kit administration will raise the amount of
                nerve agent required as a lethal dose as much as 25 times,
                markedly increasing survivability.

            b.  The unit of issue is the blister pack, which contains
                21 tablets (30 mg each), a 7 day supply. The dose is one
                (1) tablet every 8 hours, and if doses are missed, two
                tablets as a "make-up" dose should NOT be given. Instead,
                resumption of an every 8 hour schedule is preferred.      The
                onset of action is I - 3 hours and use can continue for up
                to 3 weeks before medical reevaluation is required.

            C.  Side effects are minimal, occurring in less than 1 % of
                personnel and include nild stomach cramps, nausea,
                weakness, muscle cramps, diarrhea and skin rash. In studies
                using healthy volunteers, PB did not cause any degradation
f performance when given at prescribed doses. Furthermore,
                it is safe to take with other medications. Consult medical
                personnel if significant symptoms occur.

            d. Decisions as to the initiation and cessation of use remain
                with command.

        3. POC is CPT Long, Division Surgeon's Office, 9-7663-144.



                                           J. BENJAMIN HALL/Division Surgeon

Document 1 f:/Week-22/BX001427/MISC UNIT STATUS SPOT REPORTS 28 JAN 91/pyridostigmine bromide tablets:07019618404439
Control Fields 17
File Room = jun96_declassified
File Cabinet = Week-22
Box ID = BX001427
Unit = 24TH ID
Parent Organization = XVIII CORPS
Folder Title = MISC UNIT STATUS SPOT REPORTS 28 JAN 91
Folder Seq # = 310
Subject = PYRIDOSTIGMINE BROMIDE TABLETS
Document Seq # = 39
Document Date =
Scan Date =
Queued for Declassification = 01-JAN-1980
Short Term Referral = 01-JAN-1980
Long Term Referral = 01-JAN-1980
Permanent Referral = 01-JAN-1980
Non-Health Related Document = 01-JAN-1980
Declassified = 01-JUL-1996